Advertisement
UK markets open in 42 minutes

  • NIKKEI 225

    38,220.33
    +146.35 (+0.38%)
     

  • HANG SENG

    18,916.37
    +378.56 (+2.04%)
     

  • CRUDE OIL

    79.90
    +0.64 (+0.81%)
     

  • GOLD FUTURES

    2,364.30
    +24.00 (+1.03%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • Bitcoin GBP

    50,175.66
    +934.27 (+1.90%)
     

  • CMC Crypto 200

    1,349.97
    -8.03 (-0.59%)
     

  • NASDAQ Composite

    16,346.26
    +43.46 (+0.27%)
     

  • UK FTSE All Share

    4,558.37
    +14.13 (+0.31%)
     
Money:

Best UK mortgage deals of the week

As Bank of England holds interest rates, here's what high street banks are offering home buyers

Vaccines company Valneva secures new financing with U.S firms Deerfield and OrbiMed

Reuters
·1-min read
FILE PHOTO: Biotech firm Valneva works on an inactivated whole-virus vaccine against COVID-19 in Vienna

PARIS (Reuters) - French vaccines company Valneva, which is aiming to get European approval for its COVID-19 vaccine product, said it had secured new financing with U.S.-based healthcare investment firms Deerfield Management Company and OrbiMed.

Valneva said it had agreed to increase the principal amount of its existing $60 million debt financing agreement with up to an additional $40 million with Deerfield and OrbiMed.

This extension would provide Valneva immediate access to $20 million, with an additional $20 million available upon potential conditional approval of its inactivated COVID-19 vaccine candidate, VLA2001, by the European Medicines Agency, said the company.

(Reporting by Sudip Kar-Gupta; Editing by Tom Hogue)